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in psychiatric practice: analysis of
anticonvulsant therapy
Julie Langan1*, Andrea Perry2 and Maria Oto3Abstract
Background: Anticonvulsants have been used to manage psychiatric conditions for over 50 years. It is recognised
that some, particularly valproate, carbamazepine and lamotrigine, are human teratogens, while others including
topiramate require further investigation. We aimed to appraise the documentation of this risk by psychiatrists and
review discussion around contraceptive issues.
Methods: A retrospective review of prescribing patterns of four anticonvulsants (valproate, carbamazepine,
lamotrigine and topiramate) in women of child bearing age was undertaken. Documented evidence of discussion
surrounding teratogenicity and contraceptive issues was sought.
Results: Valproate was most commonly prescribed (n=67). Evidence of teratogenic risk counselling at medication
initiation was sub-optimal – 40% of individuals prescribed carbamazepine and 22% of valproate. Documentation
surrounding contraceptive issues was also low- 17% of individuals prescribed carbamazepine and 13% of valproate.
Conclusion: We found both low rates of teratogenic risk counselling and low rates of contraception advice in our
cohort. Given the high rates of unplanned pregnancies combined with the relatively high risk of major congenital
malformations, it is essential that a detailed appraisal of the risks and benefits associated with anticonvulsant
medication occurs and is documented within patients’ psychiatric notes.
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Teratogenic potential, ContraceptionBackground
Anticonvulsants have been used in the management of
psychiatric conditions for over fifty years [1,2] particu-
larly in the management of bipolar affective disorder [3].
Semi sodium valproate is used in the treatment of acute
mania, as a maintenance therapy and in combination with
an antidepressant in bipolar depression [3]. While carba-
mazepine is recommended by the Scottish Intercollegiate
Guidelines Network (SIGN) as an alternative maintenance
therapy to lithium, particularly in patients with bipolar II
or where lithium therapy is not tolerated or is ineffective* Correspondence: Julie.langan@glasgow.ac.uk
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reproduction in any medium, provided the or[3]. Both valproate and carbamazepine are recognised as
human teratogens. The overall risk of major congenital
malformation in any pregnancy is 2% and this is increased
2–3 fold in women taking a single anticonvulsant drug
(namely valproate or carbamazepine) [4]. Studies, mostly
in women with epilepsy indicate that both medications in-
dependently increase the risk of major congenital abnor-
malities when administered in the first trimester. This
effect is not thought to be related to maternal seizure ac-
tivity [5]. Valproate in particular is associated with the
highest risk of major and minor congenital abnormality,
in particular neural tube defects [6]. There is some evi-
dence that the risk is dose dependent [7]. Valproate is also
associated with lower IQ in offspring [8]. Due to these
risks, valproate (when used as a mood stabiliser) should
not be routinely prescribed to women of childbearing
potential (SIGN 2012)(NICE 2006). Carbamazepine isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vascular and urinary tract abnormalities [9] and there is
some evidence that it reduces birth weight [10], reduces
fetal head circumference [11] and reduces gestational age
at delivery.
Lamotrigine, a newer anticonvulsant, is recommended by
SIGN in acute bipolar depression, as maintenance therapy
in individuals stabilised on this medication or where de-
pressive relapse is a greater problem than manic relapse [3].
It was initially developed as an alternative to semi sodium
valproate in epilepsy for women of child bearing potential.
Although a recent study involving the Australian Register
of Antiepileptic Drugs in pregnancy found no significant in-
creased risk of malformations for lamotrigine compared to
untreated epileptic pregnancies [12] it is recognised that
further studies are required to investigate its teratogenic po-
tential. Topiramate another new anticonvulsant has been
used off licence for weight reduction in psychiatric patients.
Currently it is not recommended by National Institute for
Health and Clinical Excellence (NICE) or SIGN in the man-
agement of mood disorders. Its teratogenic potential also
warrants further longer term study.
The use of these four medications within psychiatry is
further diversifying- with increased use “off licence”. For
example carbamazepine and valproate may be used as
adjuvants to antipsychotics in schizophrenia- [13-15]
and both along with lamotrigine may be prescribed in
the management of substance abuse (particularly alcohol
withdrawal), personality disorder, as an adjuvant in depres-
sion and in patients with cyclothymia or dementia [16]. Al-
though there have been no large scale epidemiology
studies specifically looking at prescribing rates of anticon-
vulsants for psychiatric indications in women of child bear-
ing age, it is estimated that one in twenty women of child
bearing age who are in long term contact with mental
health services are prescribed mood stabilising drugs
(many of which are anticonvulsants) [6,17]. Despite this
awareness of the teratogenic effects of these medications
amongst psychiatrists may be low.
The British National Formulary (BNF) recommends
that women of child bearing potential prescribed valpro-
ate, carbamazepine, lamotrigine and topiramate should
have contraceptive advice prior to commencing these
medications [18] although this is not mandatory. Given
that there are no specific local guidelines or inclusion in
the SIGN guidelines offering advice surrounding these
issues and a negative pregnancy test is not essential prior
to commencement; awareness of these issues in psychia-
trists may be low leading to low rates of adequate counsel-
ling. Indeed a survey of women initiated on either valproate
or carbamazepine in the psychiatric department of three
teaching hospitals over a twelve month period in England
and Wales found that “standards of documentation regard-
ing child bearing issues in this representative sample (was)poor” [19]. Given recent estimates that 50% of pregnancies
in the UK are unplanned [20,21] (and it is likely that rates
of unplanned pregnancies in the psychiatric population are
above population norms [22]) the issues of contraception,
teratogenicity counselling and the importance of docu-
menting these discussions, are particularly pertinent to
psychiatrists.
Construct and content
Aims
We aimed to survey the use of valproate, carbamazepine,
lamotrigine and topiramate for psychiatric indications in
women of child bearing age in NHS Lanarkshire to deter-
mine whether or not counselling by psychiatrists regard-
ing teratogenic risk prior to treatment commencement
occurred. We also sought to determine if contraceptive
issues had been discussed by the prescribing psychiatrist.
Method
We undertook a retrospective analysis of all secondary
care psychiatric contacts in NHS Lanarkshire, Scotland
which comprises a population of 550,000. The electronic
records were phased into mental health services over the
period 2002–2005. General adult, rehabilitation, liaison,
addiction and forensic psychiatry services all use the elec-
tronic record system. The electronic record contains all
medical outpatient letters, hospital discharge summaries
and the majority of clinical contacts between patients and
other mental health care professionals. As such it repre-
sents an accurate record of all clinical decisions including
medication changes that are made. This review was regis-
tered as a clinical audit at NHS Lanarkshire’s Research
and Development Department (Project ID 3353). Ethical
approval was not deemed required.
We searched our electronic records using the key-
words “depakote”, “semi sodium valproate”, “valproate”,
“epilim chrono”, “carbamazepine”, “tegretol”, “lamotrigine”,
“lamictal”, “topiramate” and “topamax”. All females of child
bearing age (defined as between 16 and 50) were included.
Those with a diagnosis of epilepsy were excluded and all
other ICD 10 diagnoses were included. Those with epilepsy
were excluded as the medications of interest were not
prescribed for a psychiatric indication and not initiated
by psychiatrists. Therefore any discussion surrounding
contraceptive issues would not be documented in the
psychiatric record. Individuals in whom the electronic
record was considered inadequate for analysis i.e. those in
whom the medication was commenced before the elec-
tronic record began were excluded.
All electronic records were then reviewed by JL and AP
and the relevant prescribing data was extracted from the
clinical correspondence generated at each clinical contact.
This method provides a reliable reflection of psychiatrists’
prescribing patterns as medication initiation is captured
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dence of diagnostic instability our diagnostic stratification
was based on the most prominent diagnosis by a consult-
ant psychiatrist. Reason for medication initiation was noted
along with maximum drug dosage. Defined daily dose was
calculated along with duration of treatment.
Documentation of counselling regarding teratogenic risk
at initiation of treatment by the prescribing psychiatrist
was sought. Counselling regarding teratogenic risk was de-
fined as any free text comment surrounding teratogenic ef-
fects of medication entered into the clinical record at any
clinical contact (including both outpatient review and hos-
pital discharge letter). Evidence of discussion surrounding
contraceptive issues was also sought by searching for a free
text comment surrounding this issue again at any clinical
contact. Any pregnancies at medication initiation or
subsequent to this were documented.
Results
The average number of referrals (per year) over the last
5 years for females aged between 16 and 50 to general
adult psychiatry in NHS Lanarkshire was 1,260.
606 electronic records containing our key words were
identified. 434 records were excluded due to a combin-
ation of inadequacy of record, non psychiatric indication
for medication use (e.g. epilepsy) and women not ac-
tively prescribed the medication (See Figure 1). A cohort
of 172 patients was then identified. Valproate was the most
commonly prescribed anticonvulsant (67/172, 40.0%), fol-
lowed by lamotrigine (57/172, 33.1%), carbamazepine (35/
172, 20.3%) and topiramate (13/172, 7.6%).
The average age of females prescribed the medications
of interest was similar at 39.7 years as was the age range
(20 to 50) [Table 1]. Average duration of treatment was
greater than 1 year, although the range in duration of pre-
scription was variable, with carbamazepine being pre-
scribed for 49 months on average [Table 1].Valproate 228 
identified 
Carbamazepine 
183 identified
Valproate 
67 included
T
1
Carbamazepine 
35 included
161 
excluded
148 
excluded
Figure 1 Identification of the cohort of women prescribed medicationFor all anticonvulsants a mood disorder was the most
common ICD 10 diagnosis- with valproate and topiramate
most commonly being prescribed in patients with bipolar
affective disorder. Prescription of the anticonvulsants as an
augmentation to anti-depressant medication in unipolar
depression was a commonly used strategy in our cohort
and was the most common indication for the use of carba-
mazepine and lamotrigine Unlicensed use occurred rela-
tively frequently in our cohort, including as an adjunctive
in the management of schizophrenia, schizoaffective dis-
order, emotionally unstable personality disorder and
cyclothymia [Table 1].
Evidence of counselling by the prescribing psychiatrist
regarding teratogenic risk was low amongst all four anti-
convulsants studied. Counselling rates were highest for
carbamazepine (40% n=14) followed by valproate (22%
n=15). When teratogenic risk was discussed, contracep-
tive issues were then discussed in 67% (10/15) of women
on valproate and 43% (6/14) of women on carbamazepine.
There was no documented evidence of counselling for
those prescribed lamotrigine or topiramate [Table 2].
Rates of documentation of discussion regarding contra-
ceptive issues by the prescribing psychiatrist were low oc-
curring in 17% (n=6) of cases prescribed carbamazepine
and 13% (n=10) of cases prescribed valproate. There
was no documented evidence of discussion regarding
contraceptive issues for those prescribed lamotrigine or
topiramate [Table 2]. All women, in whom contraception
was discussed, had had a discussion with their psychiatrist
around teratogenic potential of their medication.
There was no evidence of a negative pregnancy test
being required to initiate treatment in any cases in any
of the four anticonvulsants. There were five pregnancies
documented in our cohort- one occurring while on val-
proate with subsequent termination (reason unclear) and
four in women prescribed lamotrigine- with one termin-
ation (reason unclear) and three term live singleton births.Lamotrigine 
140identified
Topiramate 55 
identified 
otal cohort 
72
Lamotrigine 
57 included
Topiramate 13 
included 
83 
excluded
42 
excluded
s of interest.
Table 1 Clinical details of the anticonvulsants prescribed
Valproate (n=67) Carbamazepine (n=35) Lamotrigine (n=57) Topiramate (n=13)
Average Age years (range) 39.3 (23.6-50.0) 39.6 (20.2-50.0) 39.1 (20.2.-50.0) 40.7 (28.1-48.5)
Average duration of treatment months (range) 27 (1–91) 49 (1–238) 32 (1–90) 14 (1–62)
ICD 10 Diagnosis
Bipolar Affective Disorder % (n) 39 (26) 37 (13) 37 (21) 46 (6)
Unipolar Depression % (n) 21 (14) 43 (15) 49 (29) 38 (5)
Schizoaffective Disorder % (n) 10 (7) 0 (0) 5 (3) 0 (0)
Schizophrenia % (n) 8 (5) 0 (0) 2 (2) 0 (0)
Emotionally Unstable PD % (n) 10 (6) 6 (2) 0 (0) 8 (1)
Cyclothymia % (n) 8 (5) 3 (1) 2 (1) 0 (0)
Other % (n) 6 (4) 11 (4) 2 (1) 8 (1)
Mean dose of medication/day mg/day (range) 987 (100–2000) 455 (200–800) 166 (25–300) 192 (45–400)
Mean Dose/day (DDD)1 0.66 0.46 0.55 0.65
1DDD Defined Daily Dose, 1DDD is equivalent to valproate =1500 mg, Carbamazepine = 1000 mg, Lamotrigine = 300 mg & Topiramate = 300 mg [23].
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only one case (when valproate was prescribed). Contra-
ception had not been discussed in any of the cases.Discussion and conclusions
Carbamazepine, valproate, lamotrigine and topiramate
were prescribed for a variety of psychiatric indications in
our cohort of patients. Valproate although most commonly
used in the treatment of bipolar affective disorder was also
initiated in the management of other conditions most fre-
quently unipolar depression, schizoaffective disorder and
emotionally unstable personality disorder. Carbamazepine
and lamotrigine too were used in the management of uni-
polar depression while topiramate was most frequently
prescribed in the management of bipolar affective disorder.
Our findings are in keeping with clinical suspicion that
these medications are used for a diverse range of clinical
indications and on an offline licence basis not infrequently.
The average age of women prescribed all four medica-
tions in our cohort was similar at 39.7 years. This is older
than the 2011 Scottish average age of all women giving
birth which was 29.7 years [22]. The age range of women
prescribed these medications in our cohort was wide and
the average duration of treatment of medications was at
least 14 months, with carbamazepine typically being pre-
scribed for the longest duration at 49 months. This long
duration of exposure combined with a recent trend to-
wards older age at childbirth in Scotland is of clinicalTable 2 Rates of counselling surrounding teratogenicity & co
Valproate (n=67)
Evidence of pre-treatment teratogenic counselling % (n) 22 (15)
Documentation of discussion of contraceptive issues % (n) 13 (10)
Number of pregnancies 1relevance due to the potential risk of an unplanned preg-
nancy occurring during such a long period of exposure.
Documentation of counselling regarding teratogenic
effects and discussion of contraceptive issues by the pre-
scribing psychiatrist occurred at a low rate (<50%) in our
population studied. All women who had evidence of dis-
cussion surrounding contraceptive issues by their psych-
iatrist had evidence of counselling of the teratogenic
potential of the medication. However not all women who
were made aware of the teratogenic potential of their
medication had contraceptive issues directly discussed by
their psychiatrist. At medication initiation these important
issues were not always discussed. This finding is similar
to that found by Wieck et al20 who looked specifically at
valproate and carbamazepine. In our cohort there was a
higher rate of counselling for women prescribed carba-
mazepine compared to all other anticonvulsants including
valproate. The reasons for this are unclear, but are of note
given valproate’s higher teratogenic potential. The enzyme
inducing effect and so risk of contraceptive failure with
carbamazepine had been acknowledged in half of cases
where contraceptive issues were discussed. We found no
clear age trend in counselling rates in our cohort and this
may be due to overall small numbers who received counsel-
ling. We are unaware of any published reports concerning
the documentation of contraceptive and teratogenicity ad-
vice by psychiatrists provided to women of child bearing
potential prescribed lamotrigine or topiramate and so our
study is novel and of clinical interest. Given our findingsntraception
Carbamazepine (n=35) Lamotrigine (n=57) Topiramate (n=13)
40 (14) 0 (0) 0 (0)
17 (6) 0 (0) 0 (0)
0 4 0
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health board, results of our survey were presented to clini-
cians at the local regional teaching and an information leaf-
let for Mental Health Professionals has been developed in
association with pharmacy.
Our data appears to indicate that the prescribing psy-
chiatrists do not give sufficient advice surrounding these
issues. The reasons for this are likely multi-factorial. It is
often difficult to discuss issues surrounding longer term
complex medication side effects when patients are acutely
unwell and this may partly explain the relatively low rates
seen. However not all medications were started in an in-
patient setting, which may be a reflection of severity of ill-
ness, and a significant proportion of medication prescribed,
were initiated in the community at an outpatient appoint-
ment. Another possible explanation for the low rates of
documentation seen could be that although clinicians raise
these topics during their consultation, no written record is
made of this. This may raise issues medico-legally, for ex-
ample if a pregnancy with a congenital malformation was
to occur and there is a lack of documentation by the pre-
scribing psychiatrist surrounding teratogenic risk and
contraception in the clinical record.
Our methodology was limited by a number of factors.
Data extraction using only electronic records, may lead to
data being missed as information may be recorded else-
where such as CPN notes or other clinical paper notes.
The electronic record is used by clinicians for all out-
patient clinical contacts and discharge letters and should
represent an accurate record of all clinical decisions made,
including medication changes, potential side effects and
any other relevant drug related effects- however data may
have been omitted from this record. We also looked only
at discussion of teratogenicity and contraception at medi-
cation initiation and not at subsequent clinical contacts
and so may represent a further limitation. The small num-
bers of medications studied and a relatively small cohort
of prescribing psychiatrists may mean that our results are
influenced by independent prescribing patterns and habits
of psychiatrists. However given the similarity of our results
to others published in this field, we feel that our study is
reflective of wider practice. Teratogenic risk may have
been discussed by other health professionals including
GPs and therefore recorded out-with the electronic rec-
ord. GPs as the signatory of the prescription may inde-
pendently discuss these issues with their patients before
dispensing and record it in their primary care database.
However the purpose of our study was to determine if the
prescribing psychiatrist discussed and documented this
risk this.
Regardless of the reason for low rates of documenta-
tion it is clear that given the prevalence of anticonvul-
sant medication prescription, combined with high rates
of unplanned pregnancies and the relatively high risk ofmajor congenital malformations associated with their use,
it is imperative that a detailed discussion regarding the ap-
praisal of the risks and benefits associated with initiation
of these medications occurs and is documented within the
patient’s psychiatric notes.
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